PMC:6640909 / 115398-116322 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6640909","sourcedb":"PMC","sourceid":"6640909","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6640909","text":"Atrial fibrillation is also common in patients with LT-MCS. The effect on outcome and risk of thromboembolism is relevant. Pharmacological rhythm control strategy is widely accepted; other procedures (catheter ablation, left appendage closure) have limited evidence. Pharmacological treatment is indicated, and catheter ablation may be attempted in cases of sustained or recurrent VA. In patients with an ICD implanted prior to LT-MCS implantation, ventricular tachycardia therapy should be active to prevent adverse sequelae of right ventricular dysfunction. However, ICD settings should be very conservative. Less evidence exists for primary prevention ICD in patients without arrhythmia at the time of LVAD implantation. It might be considered not to replace a depleted ICD battery in the absence of VAs. ICD implantation is indicated for patients with LT-MCS who develop postoperative VA with haemodynamic deterioration.","tracks":[]}